

# Inhaltsverzeichnis

3/2016

Editorial <i>Editorial</i>	W. Gaebel Schizophrenie <i>Schizophrenia</i>	115
Themenschwerpunkt <i>Focus Topic</i>	Schizophrenie <i>Schizophrenia</i>	
	V. Toeller; W. Wölwer; W. Gaebel* <i>“Bridging Gaps – Improving Outcomes”</i> : Problem domains in schizophrenia research, treatment and policy	118
	S. Galderisi; F. Caputo; G. M. Giordano; A. Mucci* <i>Aetiopathological mechanisms of negative symptoms in schizophrenia</i>	121
	T. D. Cannon* <i>Predictors and mechanisms of conversion to psychosis</i>	130
	W. Gaebel; L. Wunderink; M. Riesbeck* <i>Early medication discontinuation in first episode schizophrenia – beneficial or risky?</i>	136
	A. Hasan; U. Palm; F. Padberg; T. Wobrock* <i>Brain stimulation methods for patients with schizophrenia – new therapies on the horizon?</i>	145
	I. Melle; A. O. Berg; K. Leopold; S. Zarafonitis-Müller; M. Nerhus; L. H. Stouten; A. Bechdorf* <i>Improving outcomes: Factors influencing help-seeking behaviors in immigrants and ethnic minorities with first-episode psychosis</i>	152
Diskussionsforum <i>Discussion Forum</i>	Where should we put the focus of schizophrenia research in the next five years?*	
	T. Becker; U. Gühne; K. Stengler; S. G. Riedel-Heller <i>Which research is to be prioritized in psychosocial therapies and rehabilitation?</i>	158
	S. R. Belli; T. Wykes; J. M. Haro <i>The ROAMER project – future directions and their implementation</i>	159
	B. Johnson <i>Schizophrenia research priorities from the viewpoint of patients/relatives</i>	161
	K. Wiedemann; M. Friede; C. von der Goltz <i>Which routes should psychopharmacological treatment research take in schizophrenia?</i>	162
Pharmakotherapeutisches Satellitenforum <i>Satellite Forum for Pharmacotherapy</i>	E. Ahlers Die Behandlung der ADHS im Erwachsenenalter mit retardiertem Methylphenidat <i>Treatment of adult ADHD with long-acting methylphenidate</i>	164
Verbandsnachrichten <i>Association News</i>	Mitteilungen der DGPPN	171

\*Article written in English